- Germany Takes a Bold Step: Bundestag Passes Bill to Legalize Cannabis
- Smokers’ Immune Genetic Feature Found to Lower Lung Cancer Risk
- Study of 27 Million People: Cardiovascular Disease Patients May Be More Prone to Cancer
- Unlocking the Mystery of Fatigue: Acetylcholine Therapy for Post-COVID-19 Syndrome
- Study Finds Closing Toilet Lid Does Not Reduce Virus Spread
- The century-old BCG vaccine may be the nemesis of stubborn liver cancer
CDC: mRNA COVID-19 vaccine efficiency is 94% among medical workers!
CDC: mRNA COVID-19 vaccine efficiency is 94% among medical workers! COVID-19 epidemic: 161 million! The United States Centers for Disease Control and Prevention (CDC) largest COVID-19 vaccine effectiveness study among medical workers: mRNA vaccine efficiency is 94%!
The COVID-19 pneumonia epidemic is still spreading rapidly. According to Baidu’s “New Coronavirus Pneumonia Epidemic Real-time Big Data Report”, as of 03:00 on May 15, 2021, there have been more than 160 million (16193 million) confirmed cases worldwide and more than 3.36 million deaths.
Recently, a new study from the U.S. Centers for Disease Control and Prevention (CDC) has added more and more real world evidence (RWE), indicating that the COVID- 19 The mRNA vaccine can protect health care workers (HCP) from COVID-19. In the fully vaccinated HCP population with mRNA vaccines (Pfizer/BioNTech and Moderna), the risk of developing COVID-19 disease was reduced by 94%. In this assessment, complete vaccination is defined as: 7 days or more after the second dose of vaccine.
This evaluation was conducted in a different research network, which has a larger sample size in a wider geographic area than clinical trials, independently confirming the health care work first reported on March 29 The results of the vaccine effectiveness in the United States.
CDC Director Rochelle P. Walensky, MD, said: “This report provides the most convincing information so far that the performance of the COVID-19 vaccine in the real world is consistent with expectations. This research, plus many previous studies, It is essential for the CDC to change the recommendations for those who are fully vaccinated.”
The data for this evaluation comes from a network of 500,000 HCPs covering 33 locations in 25 states in the United States, providing additional strong evidence that mRNA vaccines are effective in preventing symptomatic COVID-19 disease in the real world.
This assessment compared the vaccination status of participants who tested positive for SARS-CoV-2 (the virus that causes COVID-19) (cases) and those who tested negative (control group). Among the 1843 participants, there were 623 cases and 1220 controls. Calculate the effectiveness of the vaccine by comparing the probability of vaccinating the COVID-19 vaccine between the case group and the control group. The large sample size of this study allows an accurate estimate of vaccine effectiveness to have a narrower confidence interval (CI) than the results of an earlier study published by the CDC on March 29.
Understanding the effectiveness of vaccines in the HCP population is very important because these people are at higher risk of exposure to SARS-CoV-2 through interactions with patients. Vaccination with HCP can protect them and their patients from COVID-19 infection and ensure the continuity of critical medical services.
The evaluation found that in HCP 7 days or more after receiving the second dose of vaccination, COVID-19 symptomatic diseases were reduced by 94%, from 14 days after receiving the first dose of vaccination to 6 days after the second dose of vaccination. In the days of HCP, COVID-19 symptomatic diseases were reduced by 82%. These findings support the CDC’s recommendation that everyone should receive 2 doses of COVID-19 mRNA vaccine for maximum protection.
This assessment is part of CDC’s comprehensive strategy, which uses complementary methods to understand how the COVID-19 vaccine works in different populations and real-world environments. On May 12, the US CDC expanded its COVID-19 vaccination recommendations to include teenagers between 12 and 15 years old under the FDA’s Emergency Use Authorization (EUA). These teenagers are now authorized to receive Pfizer/BioNTech’s COVID-19 mRNA vaccine. CDC has several monitoring networks and will continue to evaluate the effects of the FDA-authorized COVID-19 vaccine in the real world on people of different age groups, including children and adolescents.
(source:internet, reference only)
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.